Citations

Clear

590 citation(s) found for "Ho, Ben".

Lead‐based ammunition is a threat to the endangered New Zealand Kea ( Nestor notabilis )
Buenz, Eric J. , Finkelstein, Myra E. , Cieraad, Ellen , Howard, Pauline, Hampton, Jordan O. , Bakker, Victoria J. , Sloan, Fiona, Hodgson, Ben, Weston, Kerry A. , Parry, Gareth J., Hunter, Simon, Hodgson, Ben

Mayo Clinic

Conservation Letters | October 23, 2024 | Volume: 17 | Issue: 6 | Pages: No page available

10.1111/conl.13059 Get It

Abstract Lead (Pb) poisoning is a significant threat to Aotearoa New Zealand's endangered kea ( Nestor notabilis ), an avian species important to Māori. Historically, exposure was thought to be from lead‐containing building materials; however, recent field observations suggest lead‐based ammunition as an additional source. We used stable lead isotopes to investigate the sources of lead to kea. Comparing 207 Pb/ 206 Pb ratios in kea blood ( n = 91) to both ammunition and building materials, we found approximately one‐third of exposed kea (blood lead > 10 µg/dL) had lead isotope ratios consistent with exposure to lead‐based ammunition. As lead ammunition is still used, including in government‐sponsored culling programs, our data indicate an urgent need to shift toward non‐lead ammunition use to prevent further poisoning and aid conservation efforts. Collaborating with tangata whenua /Māori guardians, we advocate for immediate policy changes to eliminate lead‐based ammunition in kea habitat to safeguard this endangered culturally treasured species from extinction.
Evaluation of Blood–Brain Barrier Disruption Using Low- and High-Molecular-Weight Complexes in a Single Brain Sample in a Rat Traumatic Brain Injury Model: Comparison to an Established Magnetic Resonance Imaging Technique
Zvenigorodsky, Vladislav , Gruenbaum, Benjamin F. , Shelef, Ilan , Horev, Anat , Azab, Abed N., Abu-Rabia, Mammduch, Negev, Shahar, Melamed, Israel , Boyko, Matthew , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Shelef, Ilan , Oleshko, Anna, Zlotnik, Alexander Anatolievich

Mayo Clinic

International Journal of Molecular Sciences | October 21, 2024 | Volume: 25 | Issue: 20 | Pages: 11241

10.3390/ijms252011241 | PMID 39457023 Get It

Traumatic brain injury (TBI), a major cause of death and disability among young people, leads to significant public health and economic challenges. Despite its frequency, treatment options remain largely unsuitable. However, examination of the blood–brain barrier (BBB) can assist with understanding the mechanisms and dynamics of brain dysfunction, which affects TBI sufferers secondarily to the injury. Here, we present a rat model of TBI focused on two standard BBB assessment markers, high- and low-molecular-weight complexes, in order to understand BBB disruption. In addition, we tested a new technique to evaluate BBB disruption on a single brain set, comparing the new technique with neuroimaging. A total of 100 Sprague–Dawley rats were separated into the following five groups: naive rats (n = 20 rats), control rats with administration (n = 20 rats), and TBI rats (n = 60 rats). Rats were assessed at different time points after the injury to measure BBB disruption using low- and high-molecular-weight complexes. Neurological severity score was evaluated at baseline and at 24 h following TBI. During the neurological exam after TBI, the rats were scanned with magnetic resonance imaging and euthanized for assessment of the BBB permeability. We found that the two markers displayed different examples of BBB disruption in the same set of brain tissues over the period of a week. Our innovative protocol for assessing BBB permeability using high- and low-molecular-weight complexes markers in a single brain set showed appropriate results. Additionally, we determined the lower limit of sensitivity, therefore demonstrating the accuracy of this method.
DICER1 -Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies
Schultz, Kris Ann P. , Nelson, Alexander T. , Mallinger, Paige, Harris, Anne K. , Kamihara, Junne , Baldinger, Shari , Chen, Kenneth , Pond, Dinel , Hatton, Jessica N. , Dybvik, Anna, Perrino, Melissa R. , Ami, Tal Ben , Su, Yan , Duan, Cuihai , Watson, David , Field, Amanda L., Carr, Ann G. , Schneider, Dominik T. , Schoettler, Peter , Dehner, Louis P. , Mallinger, Paige H R , Chen, Kenneth S , Dybvik, Anna G , Mitchell, Sarah G , Perrino, Melissa R , Ben-Ami, Tal , Kachanov, Denis , Su, Yan , Duan, Chao , Olson, Damon R , Watson, Dave , Field, Amanda L , Harney, Laura A , Garrity Carr, Ann , Frazier, A Lindsay , Schneider, Dominik T , Wilson, David B , MacFarland, Suzanne P , Schoettler, Peter J , Bauer, Andrew J , Dehner, Louis P , Hill, Dana Ashley , Stewart, Douglas R , Messinger, Yoav H , Harris, Anne K , Olson, Damon R. , Wilson, David B. , Messinger, Yoav H.

Mayo Clinic

Clinical Cancer Research | October 14, 2024 | Volume: 30 | Issue: 24 | Pages: 5681-5692

10.1158/1078-0432.ccr-24-1532 | PMID 39400264 Get It

Abstract Purpose: DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing- and imaging-based surveillance of individuals with a known or suspected germline DICER1 pathogenic or likely pathogenic (P/LP) variant. One of the goals of the Registry is to continue to refine these guidelines as additional data become available. Experimental Design: Individuals were enrolled in the International PPB/DICER1 Registry, the International Ovarian and Testicular Stromal Tumor Registry, and/or the NCI Natural History of DICER1 Syndrome study. Results: Review of participant records identified 713 participants with a germline DICER1 P/LP variant from 38 countries. To date, 5 cases of type I and 29 cases of type Ir PPB have been diagnosed by surveillance in enrolled individuals. One hundred and three individuals with a germline P/LP variant developed a primary ovarian Sertoli–Leydig cell tumor at a median age of 14 years (range: 11 months–66 years); 13% were diagnosed before 8 years of age, the current age of onset of pelvic surveillance. Additionally, 4% of Sertoli–Leydig cell tumors were diagnosed before 4 years of age. Conclusions: Ongoing data collection highlights the role of lung surveillance in the early detection of PPB and suggests that imaging-based detection and early resection may decrease the risk of advanced PPB. DICER1-related ovarian tumors were detected before 8 years of age, prompting the Registry to recommend earlier initiation of ovarian surveillance with pelvic ultrasound beginning at the time of detection of a germline DICER1 P/LP variant.
Rethinking Measures and Mortality Attribution in Health Care: The ENT Example
Patel, Samip , Olivero, Lorenzo , FRÍAS, JORGE SINCLAIR DE , Anderson, Stephanie S., Pollock, Ben D., Lee, Marian D., Chirilă, Răzvan M. , Guru, Pramod , Pollock, Benjamin D. , Sinclair, Jorge Enrique , Guru, Pramod K , Taylor, Richard, Moreno Franco, Pablo , Patel, Samip N , Pollock, Benjamin D , Lee, Marian D., Murthy, Hemant S. , Taylor, Richard A. , Franco, Pablo Moreno , Menser, Terri

Mayo Clinic

Otolaryngology–Head and Neck Surgery | October 13, 2024 | Volume: 171 | Issue: 6 | Pages: 1925-1927

10.1002/ohn.1015 | PMID 39396155 Get It

AbstractNational performance metrics ultimately enhance patient decision‐making and promote meaningful improvements in health care delivery, which makes having valid and reliable measures essential. This study examined US News and World Report metrics from 2019 to 2012 and used electronic health record data, combined with detailed chart review across 3 in‐system hospitals, to assess the provision of care compared to the attribution of patients assigned to the ear, nose, and throat (ENT) mortality group. Of the initial 47 ENT‐attributed deaths, 23 of those were verified, dimensioning the mortality rate from 1.7% to just 0.8%. These results underscore the necessity of rethinking measures and mortality attribution methodologies to be more accurate. Current methods use Medicare Severity Diagnosis Related Group billing coding to map the attribution. We suggest transitioning away from specialty ranking approaches and towards a procedure and condition “rating” approach to ensure that these ranking types capture data about the provision of care within a given encounter.
Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli
Tchétché, Didier , Blackman, Daniel J. , Khalil, Ramzi F., Möllmann, Helge , Abdel‐Wahab, Mohamed , Ali, Walid Ben, Mahoney, Paul, Ruge, Hendrik, Lin, Lang, Byku, Isida , Gillam, Linda D. , Petronio, Anna Sonia , Attizzani, Guilherme F. , Batchelor, Wayne , Gada, Hemal, Rovin, Joshua D. , Benton, Stewart M., Gardner, Blake, Padang, Ratnasari , Herrmann, Howard C., Ruge, Hendrik , Ali, Walid Ben , Mehran, Roxana , Khalil, Ramzi F. , Bleiziffer, Sabine , Szerlip, Molly , Grubb, Kendra J , Guerrero, Mayra , Rogers, Toby , Whisenant, Brian K. , Althouse, Andrew D. , Herrmann, Howard C.

Mayo Clinic

JAMA Cardiology | October 9, 2024 | Volume: 9 | Issue: 12 | Pages: 1106

10.1001/jamacardio.2024.3241 | PMID 39382856 Get It

Importance Historically, women with aortic stenosis have experienced worse outcomes and inadequate recognition compared to men, being both underdiagnosed and undertreated, while also facing underrepresentation in clinical trials. Objective To determine whether women with small aortic annuli undergoing transcatheter aortic valve replacement have better clinical and hemodynamic outcomes with a self-expanding valve (SEV) or balloon-expandable valve (BEV). Design, Setting, Participants The Small Annuli Randomized to Evolut or SAPIEN Trial (SMART) was a large-scale randomized clinical trial focusing on patients with small aortic annuli undergoing transcatheter aortic valve replacement, randomized to receive SEVs or BEVs and included 716 patients treated at 83 centers in Canada, Europe, Israel, and the US from April 2021 to October 2022. This prespecified secondary analysis reports clinical and hemodynamic findings for all 621 women enrolled in SMART. Data for this report were analyzed from February to April 2024. Interventions Transcatheter aortic valve replacement with an SEV or a BEV. Main Outcomes and Measures The composite coprimary clinical end point comprised death, disabling stroke, or heart failure–related rehospitalization. The coprimary valve function end point was the incidence of bioprosthetic valve dysfunction, both assessed through 12 months. Secondary end points included the incidence of moderate or severe prosthesis-patient mismatch. Results A total of 621 women (mean [SD] age, 80.2 [6.2] years; 312 randomized to the SEV group and 309 to the BEV group) were included in the present analysis. At 12 months, there were no significant differences in the coprimary clinical end point between the SEV and BEV groups (9.4% vs 11.8%, absolute risk difference −2.3%; 95% CI −7.2 to 2.5, P = .35). However, SEV implantation was associated with less bioprosthetic valve dysfunction (8.4% vs 41.8%; absolute risk difference, −33.4%; 95% CI, −40.4 to −26.4; P < .001). SEV implantation resulted in lower aortic valve gradients and larger effective orifice areas at 30 days and 12 months and less mild or greater aortic regurgitation at 12 months compared to BEV implantation. Prosthesis-patient mismatch was significantly lower with SEVs, regardless of the definition used and adjustment for body mass index. Use of SEVs was associated with better quality of life outcomes as assessed by the Valve Academic Research Consortium-3 ordinal quality of life measure. Conclusions and Relevance Among women with severe symptomatic aortic stenosis and small aortic annuli undergoing transcatheter aortic valve replacement, the use of SEVs, compared to BEVs, resulted in similar clinical outcomes and a markedly reduced incidence of bioprosthetic valve dysfunction through 12 months, including a lower risk of prosthesis-patient mismatch and better 12-month quality of life. Trial Registration ClinicalTrials.gov Identifier: NCT04722250
Somatic, emotional, and gastrointestinal symptom severity are increased among children and adolescents with COVID‐19
Berken, Jonathan A. , Keeley, Kaitlyn, Katz, Ben Z. , Fortunato, John E. , Saps, Miguel , Wechsler, Joshua B , Saps, Miguel , Singer, Wolfgang , Jhaveri, Ravi R.

Mayo Clinic

Neurogastroenterology & Motility | September 3, 2024 | Volume: 36 | Issue: 11 | Pages: No page available

10.1111/nmo.14909 | PMID 39223749 Get It

AbstractBackgroundPost‐infectious disorders of gut‐brain interaction (PI‐DGBI) have significant impact on children and adolescents. The effect of COVID‐19 on PI‐DGBI‐associated symptoms in this population, however, is unknown.MethodsWe performed electronic medical record searches to identify patients 8–17 years old with a SARS‐CoV2 PCR test at Lurie Children's Hospital between November 2020 and March 2021 (cohort 1) and April–October 2021 (cohort 2). Questionnaires were administered to assess symptoms prior to and 3 months following the test. This included the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS), questionnaire of pediatric gastrointestinal symptoms—Rome IV, Nausea Profile (NP), dyspepsia symptom survey (DSS), nausea severity profile (NSP), and Pediatric Quality of Life Inventory (PedsQL). We grouped patients based on the presence of symptoms prior to COVID‐19 test or the test result.ResultsOne hundred and ninety‐six parent(s) or guardian(s) in cohort 1 and 274 in cohort 2 completed surveys and self‐reported their child's COVID‐19 result. Cohort 1 had increased PEESS and DSS scores, lower PedsQL scores, and increased frequency of abdominal pain disorders among patients with symptoms prior to COVID‐19 testing. Both cohorts had increased NP and NSP scores among patients with symptoms prior to COVID‐19 testing that was highest among patients with a positive COVID‐19 test. Abdominal pain and diarrhea prior to COVID‐19 testing predicted higher NP scores.ConclusionsAmong symptomatic COVID‐19 tested children, we found increased severity of nausea‐associated somatic, emotional, and gastrointestinal symptoms in the 3 months following the test that was most increased among patients with a positive COVID‐19 test.
RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2 -Mutated Clonal Hematopoiesis
Ben-Crentsil, Nana Adjoa , Ismail, Wazim Mohammed , Newman, Hannah , Quintana, Ariel , Binder, Moritz , Kruer, Traci , Neupane, Surendra , Ferrall‐Fairbanks, Meghan C. , Fernandez, Jenna , Finke, Christy M. , Ibrahim, Mohammed L. , McGraw, Kathy L. , Wysota, Michael , Aldrich, Amy L. , Letson, Christopher T. , Traina, Joshua , McLemore, Amy F. , Droin, Nathalie , Sallman, David A. , Beg, Amer A. , Ma, Li , Gaspar‐Maia, Alexandre , Patnaik, Mrinal M. , Padron, Eric , Mohammed Ismail, Wazim , Balasis, Maria , Newman, Hannah , Quintana, Ariel , Binder, Moritz , Kruer, Traci , Neupane, Surendra , Ferrall-Fairbanks, Meghan C , Fernandez, Jenna , Lasho, Terra L , Finke, Christy M , Ibrahim, Mohammed L , McGraw, Kathy L , Wysota, Michael , Aldrich, Amy L , Ryder, Christopher B , Letson, Christopher T , Traina, Joshua , McLemore, Amy F , Droin, Nathalie , Shastri, Aditi , Yun, Seongseok , Solary, Eric , Sallman, David A , Beg, Amer A , Ma, Li , Gaspar-Maia, Alexandre , Patnaik, Mrinal , Padron, Eric , Balasis, Maria E. , Lasho, Terra L. , Yun, Seongseok , Solary, Éric

Mayo Clinic

Cancer Discovery | August 27, 2024 | Volume: 14 | Issue: 12 | Pages: 2509-2531

10.1158/2159-8290.cd-24-0093 | PMID 39189614 Get It

Abstract TET2 mutations (mTET2) are common genetic events in myeloid malignancies and clonal hematopoiesis. These mutations arise in the founding clone and are implicated in many clinical sequelae associated with oncogenic feedforward inflammatory circuits. However, the direct downstream effector of mTET2 responsible for the potentiation of these inflammatory circuits is unknown. To address this, we performed scRNA-seq and scATAC-seq in patients with COVID-19 with and without TET2-mutated clonal hematopoiesis reasoning that inflammation from COVID-19 may highlight critical downstream transcriptional targets of mTET2. Using this approach, we identified metastasis-associated lung adenoma transcript 1 (MALAT1), a therapeutically tractable lncRNA, as a central downstream effector of mTET2 that is both necessary and sufficient to induce the oncogenic proinflammatory features of mTET2 in vivo. We also elucidate the mechanism by which mTET2 upregulate MALAT1 and describe an interaction between MALAT1 and p65, which leads to RNA “shielding” from protein phosphatase 2A dephosphorylation, thus preventing resolution of inflammatory signaling. Significance: This work identifies MALAT1 as a requisite downstream effector of oncogenic feedforward inflammatory circuits necessary for the development of TET2-mutated CH and fulminant myeloid malignancy. We elucidate a novel mechanism by which MALAT1 “shields” p65 from dephosphorylation to potentiate this circuit and nominate MALAT1 inhibition as a future therapeutic strategy.
The effect of Mankai plant consumption on postprandial glycaemic response among patients with type 2 diabetes: A randomized crossover trial
Tsaban, Gal , Aharon‐Hananel, Genya, Shalem, Shiran, Zelicha, Hila , Meir, Anat Yaskolka , Pachter, Dafna , Goldberg, D , Kamer, Omer , Alufer, Liav , Stampfer, Meir J. , Qi, Lu , Blüher, Matthias , Hu, Frank B., Shai, Iris , Qi, Lu , Blüher, Matthias , Yaskolka Meir, Anat , Shai, Iris , Goldberg, Dana Tamar , Wang, Dong D. , Stümvoll, Michael , Tirosh, Amir

Mayo Clinic

Diabetes, Obesity and Metabolism | August 12, 2024 | Volume: 26 | Issue: 10 | Pages: 4713-4723

10.1111/dom.15840 | PMID 39134456 Get It

Abstract Aim To explore the effect of Mankai, a cultivated aquatic duckweed green plant, on postprandial glucose (PG) excursions in type 2 diabetes (T2D). Methods In a 4‐week, randomized crossover‐controlled trial, we enrolled 45 adults with T2D (HbA1c range: 6.5%‐8.5%) from two sites in Israel. Participants were randomized to drink Mankai (200 mL of raw‐fresh‐aquatic plant + 100 mL of water, 40 kcal, ~10 g of dry matter equivalent) or water (300 mL) following dinner, for 2 weeks each, with a 4‐day washout interval, without dietary, physical activity or pharmacotherapy alterations. We used continuous glucose monitoring (CGM) devices. Results Forty patients (adherence rate = 88.5%; 743 person‐intervention‐days, 68.9% men, age = 64 years, HbA1c = 6.8%) completed the study with a consistent diet and complete CGM reads. Only two‐thirds of the individuals responded beneficially to Mankai. Overall, Mankai significantly lowered the PG peak by 19.3% (∆peak = 24.3 ± 16.8 vs. 30.1 ± 18.5 mg/dL; P < .001) and delayed the time‐to‐peak by 20.0% (112.5 [interquartile range: 75‐135] vs. 90 [60‐105] min; P < .001) compared with water. The PG incline and decline slopes were shallower following postdinner Mankai (incline slope: 16.8 vs. water: 29.9 mg/[dL h]; P < .001; decline slope: −6.1 vs. water: −7.9 mg/[dL h]; P < .01). Mean postprandial net incremental area‐under‐the‐glucose‐curve was lowered by 20.1% with Mankai compared with water ( P = .03). Results were consistent across several sensitivity and subgroup analyses, including across antidiabetic pharmacotherapy treatment groups. Within 2 weeks, the triglycerides/high‐density lipoprotein cholesterol ratio in the Mankai group (−0.5 ± 1.3) decreased versus water (+0.3 ± 1.5, P = .05). Conclusions Mankai consumption may mitigate the PG response in people with T2D with an ~20% improvement in glycaemic values. These findings provide case‐study evidence for plant‐based treatments in T2D to complement a healthy lifestyle and pharmacotherapy.
Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia
Chang, Ti‐Cheng , Chen, Wenan , Cheng, Zhongshan , Hedges, Dale J., Elsayed, Abdelrahman , Pounds, Stanley , Shago, Mary , Rabin, Karen R. , Raetz, Elizabeth A. , Cheng, Cheng , Angiolillo, Anne , Baviskar, Pradyuamna , Borowitz, Michael J., Carroll, Andrew J. , Carroll, William L. , Heerema, Nyla A. , Larsen, Eric , Mattano, Leonard A. , Maloney, Kelly W. , Ramirez, Nilsa C. , Salzer, Wanda L. , Wu, Gang , Loh, Mignon L. , Wu, Gang , Rabin, Karen R , Raetz, Elizabeth A , Devidas, Meenakshi , Baviskar, Pradyuamna , Burke, Michael J , Carroll, Andrew J , Harvey, Richard , Iacobucci, Ilaria , Wang, Jeremy R , Jeha, Sima , Mattano, Leonard A , Maloney, Kelly W , Pui, Ching-Hon , Ramirez, Nilsa C , Willman, Cheryl , Wood, Brent L , Hunger, Stephen P , Mullighan, Charles G , Loh, Mignon L , Pounds, Stanley B , Wu, Gang , Qu, Chunxu , Devidas, Meenakshi , Chen, I‐Ming , Harvey, Richard C. , Iacobucci, Ilaria , Wang, Jeremy , Willman, Cheryl L. , Winick, Naomi Joan , Wood, Brent L. , Hunger, Stephen P. , Mullighan, Charles G.

Mayo Clinic

Journal of Clinical Oncology | August 9, 2024 | Volume: 42 | Issue: 29 | Pages: 3491-3503

10.1200/jco.23.02238 | PMID 39121442 Get It

PURPOSE Although cure rates for childhood acute lymphoblastic leukemia (ALL) exceed 90%, ALL remains a leading cause of cancer death in children. Half of relapses arise in children initially classified with standard-risk (SR) disease. MATERIALS AND METHODS To identify genomic determinants of relapse in children with SR ALL, we performed genome and transcriptome sequencing of diagnostic and remission samples of children with SR (n = 1,381) or high-risk B-ALL with favorable cytogenetic features (n = 115) enrolled on Children's Oncology Group trials. We used a case-control study design analyzing 439 patients who relapsed and 1,057 who remained in complete remission for at least 5 years. RESULTS Genomic subtype was associated with relapse, which occurred in approximately 50% of cases of PAX5 -altered ALL (odds ratio [OR], 3.31 [95% CI, 2.17 to 5.03]; P = 3.18 × 10 –8 ). Within high-hyperdiploid ALL, gain of chromosome 10 with disomy of chromosome 7 was associated with favorable outcome (OR, 0.27 [95% CI, 0.17 to 0.42]; P = 8.02 × 10 –10 ; St Jude Children's Research Hospital validation cohort: OR, 0.22 [95% CI, 0.05 to 0.80]; P = .009), and disomy of chromosomes 10 and 17 with gain of chromosome 6 was associated with relapse (OR, 7.16 [95% CI, 2.63 to 21.51]; P = 2.19 × 10 –5 ; validation cohort: OR, 21.32 [95% CI, 3.62 to 119.30]; P = .0004). Genomic alterations were associated with relapse in a subtype-dependent manner, including alterations of INO80 in ETV6::RUNX1 ALL, IKZF1 , and CREBBP in high-hyperdiploid ALL and FHIT in BCR::ABL1 -like ALL. Genomic alterations were also associated with the presence of minimal residual disease, including NRAS and CREBBP in high-hyperdiploid ALL. CONCLUSION Genetic subtype, patterns of aneuploidy, and secondary genomic alterations determine risk of relapse in childhood ALL. Comprehensive genomic analysis is required for optimal risk stratification.